证券代码：600030 证券简称：中信证券 公告编号：临2025-062 中信证券股份有限公司 2024年度A股权益分派实施公告 公司已派发2024年度中期现金红利每股人民币0.24元（含税），连同本次 现金红利分配，2024年全年现金红利为每股人民币0.52元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/8/22 | － | 2025/8/25 | 2025/8/25 | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次每股分配比例 A股每股现金红利0.28元（含税） 差异化分红送转：否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经中信证券股份有限公司（以下简称公司）于2025年6月27 日召开的2024年度股东大会审议通过。 二、分配方案 1. 发放年度：2024年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算 ...

证券代码：600030 证券简称：中信证券 公告编号：临2025-061 中信证券股份有限公司 关于间接子公司发行中期票据 并由全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | CSI MTN | Limited | | --- | --- | --- | --- | | | 本次担保金额 | 2,050万美元 | | | 担保对象 | 实际为其提供的担保余额 | 32.79亿美元 | | | | 是否在前期预计额度内 | □否 是 | □不适用 | | | 本次担保是否有反担保 | □是 否 | □不适用 | 累计担保情况 | 对外担保逾期的累计金额（万元） | - | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（亿元） | 1,746.92 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 59.60 | | 特别风险提示 | □对外担保总额超过最近一期经审计净资产 | | | ...

格隆汇8月18日｜融创官微宣布，由中信、新湖、融创联合开发的上海壹号院五批次结束认筹。本批次 共推出66套315-1115平米大户型产品，认筹率超200%。上海壹号院五批次将于8月23日正式开盘。 ...

中信证券成交额达100亿元，现涨近2%。 ...

Core Viewpoint - 华大九天's 2025 semi-annual report indicates a mixed financial performance with a revenue increase but a significant decline in net profit [1][2]. Financial Performance Summary - The company achieved an operating revenue of 5.02 billion yuan, representing a year-on-year growth of 13.01% [1][2]. - The net profit attributable to shareholders decreased to 3.07 million yuan, down 91.90% compared to the previous year [1][2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -18.62 million yuan, an improvement of 63.66% from -51.25 million yuan in the same period last year [1][2]. - The net cash flow from operating activities was 2.43 billion yuan, a significant increase of 4,475.60% from -555.84 thousand yuan in the previous year [1][2]. Fundraising and Use of Proceeds - 华大九天 raised a total of 354.98 million yuan from its IPO, with a net amount of 346.60 million yuan after deducting issuance costs [3]. - The final net fundraising amount exceeded the original plan by 91.49 million yuan [3]. - The funds are intended for various EDA tool upgrade projects and to supplement working capital [3].

人民财讯8月18日电，中信证券研报认为，上半年内需呈现出一定复苏态势，但居民消费仍有较大提升 空间，尤其是在下半年出口面临不确定性的背景下，中国政策端持续发力提振内需的大方向明确，增量 消费政策持续落地有望对消费形成改观，建议关注"新消费"的结构性机会以及"传统消费"基本面触底回 升机会。 ...

每经AI快讯，中信证券研报表示，产品端从车险一枝独秀到非车险百花齐放、定价端从同质化到差异 化、政策端从统颁条款到鼓励创新、经营端从野蛮生长到效益为先，行业正从财险1.0时代向财险2.0时 代跃迁。我们认为以往低价竞争式的粗放发展模式将不可持续，下一阶段行业竞争的重点将聚焦于风险 定价、风险勘察、风险减量三位一体的专业能力建设，术业专精的头部财险公司有望强者恒强。 ...

Core Viewpoint - The report from CITIC Securities indicates that the banking sector is experiencing a narrowing decline in interest margins, stable asset quality, and improved performance growth in the second quarter, with expectations for a continued gradual improvement in subsequent quarters of the year [1] Group 1: Banking Sector Performance - The banking sector's interest margin decline has narrowed, indicating a potential stabilization in profitability [1] - Asset quality remains stable, suggesting that banks are managing their credit risks effectively [1] - Performance growth is improving, which may lead to a more favorable outlook for the sector in the near term [1] Group 2: Future Expectations - It is anticipated that the trends observed in the second quarter will continue to improve gradually throughout the year [1] - The banking sector is expected to experience a revaluation of net assets, indicating a potential for long-term growth [1] - Short-term fluctuations may occur due to the influence of market styles and the inflow of trading funds, highlighting the importance of sustained investment [1] Group 3: Valuation Insights - The report suggests that the banking sector's valuation may remain below one times net assets, indicating room for recovery [1] - Absolute returns are still expected, emphasizing the potential for investment opportunities despite market volatility [1]

Core Viewpoint - Huasheng Biotechnology has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International and CITIC Securities serving as joint sponsors [1] Company Overview - Established in 2012, the company is a biopharmaceutical firm based in China, focusing on the development of protein drugs, particularly in the wound healing sector [1] - The company has two core products in its pipeline: Pro-101-1 for treating burns and Pro-101-2 for diabetic foot ulcers [1] Product Development - Pro-101-1 has completed Phase IIb clinical trials in China and is currently in the clinical trial report confirmation stage [1] - Pro-101-2 is undergoing Phase II clinical trials in China [1] - The company anticipates that its PDGF candidate products will primarily target the Chinese market, with plans to launch Pro-101-1 in the United States [1] Market Position - Pro-101-1 is noted as the fastest-developing PDGF candidate drug for burn treatment in China, where there are currently no commercialized PDGF drugs [1] Intellectual Property - The company has submitted five patent applications for its core products and has obtained two PDGF-related patents and technical data from Jingbang and the Military Academy of Engineering in 2013 [1]

智通财经APP获悉，8月13日,信达生物（01801）、中国人寿（02628）、友邦保险（01299）南向资金 净流入金额位列市场前三，分别净流入8.35 亿、4.03 亿、3.73 亿 盈富基金（02800）、恒生中国企业（02828）、安踏体育（02020）南向资金净流出金额位列市场前 三，分别净流出-66.79 亿、-25.84 亿、-7.82 亿 | 股票名称 | 净流入(元)↓ | 净流入比 | 收盘价 | | --- | --- | --- | --- | | 信达生物(01801) | 8.35 亿 | 33.64% | 95.000（+8.82%） | | 中国人寿(02628) | 4.03 亿 | 21.25% | 22.800（+0.71%） | | 友邦保险(01299) | 3.73 亿 | 13.36% | 76.400（+3.03%） | | 理想汽车-W(02015) | 3.65 亿 | 13.55% | 97.150（+3.30%） | | 石药集团(01093) | 2.57 亿 | 14.56% | 10.720（+6.77%） | | 中国生物制药(01177) | ...